Last updated on November 2019

Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.

Brief description of study

This is a phase IIa, double-blind, randomised, placebo-controlled, multi-center study to evaluate the effects of estetrol on testosterone suppression and quality of life in prostate cancer patients treated with an LHRH agonist. Patients will be treated with estetrol or placebo for 6 months.

Clinical Study Identifier: NCT03361969

Find a site near you

Start Over

Ziekenhuis Amstelland

Amstelveen, Netherlands
  Connect »